The EVESOR trial, a phase 1 trial (NCT01932177), focused on the combination treatment of everolimus (an mTOR inhibitor) and sorafenib (a VEGF inhibitor) in 43 cancer patients with various solid tumors, including a subset of 23.2% with CCA. This evidence concerns the gene MTOR and cholangiocarcinoma.